mRNA Technology Beyond COVID-19: French Researchers Pioneer New Cancer Therapies
Table of Contents
A surge in research is exploring the potential of messenger RNA (mRNA) too revolutionize cancer treatment and bolster the immune system,building on the success of mRNA vaccines developed during the COVID-19 pandemic. New findings, unveiled in conjunction with the World Day against Pancreatic Cancer, highlight innovative approaches being spearheaded by researchers at the National institute of Health and Medical Research in France (INSERM).
The Promise of mRNA: From Vaccines to Cancer Treatment
The rapid advancement of COVID-19 vaccines demonstrated the remarkable flexibility and speed of mRNA technology, a breakthrough recognized with the 2023 Nobel Prize for Medicine. While previously known since the 1960s, the pandemic accelerated its request, opening doors to a wider range of medical possibilities. Currently, the majority of studies are focused on personalized cancer vaccines, but experts beleive the potential extends far beyond oncology, encompassing treatments for rare genetic diseases, cellular disorders, and even allergies.
Pioneering Research in Orléans
In a laboratory located in Orléans, France, researchers are meticulously testing various forms of mRNA – molecules that deliver genetic instructions for protein production within the body’s cells. Specialists at the ART laboratory of the INSERM Institute are investigating how these genetic messages can effectively stimulate the immune system to identify and combat cancerous tumors.
“We are looking at how to harness the power of mRNA to teach the immune system to recognize and destroy cancer cells,” a senior researcher explained.
Addressing the Cost Barrier: Yeast-Based mRNA Production
A significant hurdle in widespread mRNA adoption is the high cost of production, often constrained by patents held by US companies. to overcome this, the INSERM team is exploring a novel method: producing RNA in yeast. This innovative approach could possibly reduce manufacturing costs by a considerable 10 to 50 times. However, rigorous purification processes are essential to ensure the yeast-produced molecules meet the stringent standards required by the pharmaceutical industry.
A novel Approach to Pancreatic Cancer
Researchers are focusing specifically on pancreatic cancer, one of the most aggressive and deadly forms of the disease. Despite a doubling of the five-year survival rate over the past two decades – from 5% in 2000 to approximately 10% today – progress remains limited, and conventional treatments like chemotherapy and immunotherapy offer modest benefits.
To address this challenge,French scientists are pioneering a combined therapy utilizing an mRNA vaccine alongside ultrasound technology. High-intensity ultrasounds generate vibrations within tissues, creating gas microbubbles. These microbubbles, upon controlled implosion, can disrupt the dense barriers surrounding pancreatic tumors, a process described as “permeabilizing” the tissue. This enhanced permeability allows the mRNA vaccine to more effectively reach the tumor, instructing immune cells to target and destroy the cancer.
Early results indicate that ultrasound can be safely applied to the pancreas and can improve patient response to existing treatments. The next crucial step is to determine how this combination therapy can ultimately increase survival rates for patients battling pancreatic cancer.
Global Efforts and a Grim Reality
More than 200 clinical trials involving mRNA are currently underway globally, conducted by both major pharmaceutical companies and emerging start-ups in the United States, China, Japan, and beyond. France is recognized for its robust essential research teams in this rapidly evolving field.
Pancreatic cancer remains a devastating disease, ranking as the sixth leading cause of cancer-related deaths worldwide. With a five-year survival rate of only a few percent, the disease is projected to claim approximately 470,000 lives globally this year. The research unveiled on the World Day against Pancreatic Cancer, observed annually on the third Thursday of november, underscores the urgent need for innovative therapies and increased awareness of this critical health challenge.
